Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics Q1 revenue rises 11% to $187 million; 2026 revenue outlook raised

Positive Impact 4 of 5 earnings Written later

NeoGenomics reported first quarter 2026 revenue of $187 million, up 11% from a year earlier, and a net loss of $17 million, down 34%. The company raised its full-year 2026 revenue guidance to $797 million-$803 million from $793 million-$801 million, while its net loss and Adjusted EBITDA guidance were unchanged.

Key points

  • Q1 2026 revenue was $187 million, up 11%, with Clinical revenue up 14%.
  • Net loss narrowed to $17 million from $26 million in Q1 2025; Adjusted EBITDA was $9 million, up 27%.
  • FY 2026 revenue guidance raised to $797 million-$803 million; net loss guidance of $(63) million to $(50) million and Adjusted EBITDA guidance of $55 million-$57 million were unchanged.

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECApr 28, 2026, 4:59 PM ET
Accession number0001077183-26-000022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.